These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 36547230)
1. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis. Chen C; Zhang L; Ruan Z Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230 [TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis. Yin L; Wang Y Cancer Immunol Immunother; 2023 Mar; 72(3):743-758. PubMed ID: 36319716 [TBL] [Abstract][Full Text] [Related]
3. Delivery of SIRT1 by cancer-associated adipocyte-derived extracellular vesicles regulates immune response and tumorigenesis of ovarian cancer cells. Zheng Q; Du X; Zhang J; Liu Y; Dong W; Dai X; Gu D Clin Transl Oncol; 2024 Jan; 26(1):190-203. PubMed ID: 37311988 [TBL] [Abstract][Full Text] [Related]
4. The biological roles of CD24 in ovarian cancer: old story, but new tales. Gu Y; Zhou G; Tang X; Shen F; Ding J; Hua K Front Immunol; 2023; 14():1183285. PubMed ID: 37359556 [TBL] [Abstract][Full Text] [Related]
5. LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer. Liu J; Yan C; Xu S Cell Death Dis; 2024 May; 15(5):313. PubMed ID: 38702326 [TBL] [Abstract][Full Text] [Related]
6. TAM-derived extracellular vesicles containing microRNA-29a-3p explain the deterioration of ovarian cancer. Lu L; Ling W; Ruan Z Mol Ther Nucleic Acids; 2021 Sep; 25():468-482. PubMed ID: 34589270 [TBL] [Abstract][Full Text] [Related]
7. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043 [TBL] [Abstract][Full Text] [Related]
8. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430 [TBL] [Abstract][Full Text] [Related]
9. CD24-Siglec axis is an innate immune checkpoint against metaflammation and metabolic disorder. Wang X; Liu M; Zhang J; Brown NK; Zhang P; Zhang Y; Liu H; Du X; Wu W; Devenport M; Tao W; Mao-Draayer Y; Chen GY; Chen YE; Zheng P; Liu Y Cell Metab; 2022 Aug; 34(8):1088-1103.e6. PubMed ID: 35921817 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099 [TBL] [Abstract][Full Text] [Related]
11. Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Toubai T; Hou G; Mathewson N; Liu C; Wang Y; Oravecz-Wilson K; Cummings E; Rossi C; Evers R; Sun Y; Wu J; Choi SW; Fang D; Zheng P; Liu Y; Reddy P Blood; 2014 May; 123(22):3512-23. PubMed ID: 24695850 [TBL] [Abstract][Full Text] [Related]
12. miR-106a-5p carried by tumor-derived extracellular vesicles promotes the invasion and metastasis of ovarian cancer by targeting KLF6. Zheng Y; Zhu K; Wang G Clin Exp Metastasis; 2022 Aug; 39(4):603-621. PubMed ID: 35449340 [TBL] [Abstract][Full Text] [Related]
13. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity. Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782 [TBL] [Abstract][Full Text] [Related]
14. Novel insights into the function of CD24: A driving force in cancer. Altevogt P; Sammar M; Hüser L; Kristiansen G Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899 [TBL] [Abstract][Full Text] [Related]
15. Kynurenine in IDO1 Ying X; Zheng X; Zhang X; Yin Y; Wang X J Transl Med; 2024 Mar; 22(1):267. PubMed ID: 38468343 [TBL] [Abstract][Full Text] [Related]
16. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998 [TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicle-packaged miR-181c-5p from epithelial ovarian cancer cells promotes M2 polarization of tumor-associated macrophages via the KAT2B/HOXA10 axis. Yang S; Zhao H; Xiao W; Shao L; Zhao C; Sun P J Gene Med; 2022 Oct; 24(10):e3446. PubMed ID: 36027869 [TBL] [Abstract][Full Text] [Related]
18. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression. Li Y; Zhou J; Zhuo Q; Zhang J; Xie J; Han S; Zhao S Cancer Manag Res; 2019; 11():7123-7134. PubMed ID: 31534365 [No Abstract] [Full Text] [Related]
19. Siglec-9 Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296 [TBL] [Abstract][Full Text] [Related]
20. Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies. Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S Immunology; 2024 Nov; 173(3):442-469. PubMed ID: 39129256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]